Datapoint: FDA Snubs Biocon’s Avastin Biosimilar

The FDA last week rejected Biocon’s Bevacizumab, a biosimilar to Roche’s blockbuster oncology drug Avastin, according to the Center for Biosimilars. Biocon gave few details on the rejection, but it likely stems from issues following an Aug. 22 manufacturing inspection. Avastin was first approved in 2004 for the treatment of colorectal cancer, an indication for which it currently holds covered or better status for 43% of insured lives under the pharmacy benefit, and 86% under the medical benefit.

SOURCE: MMIT Analytics, as of 2/15/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today